hopefully management is moving past spending time on the 13D group - i think we all should. a lot of ink being spilled - and they are a bunch of clowns, and are not our big threat. the real threat / challenge is well funded highly professional pharma companies with MABs already approved - and i can't imagine they're not all exploring other indications for their compounds.

Thus, our focus needs to be 100% about getting to market. I'd be in favor of a partnership and soon - give a little bit up to make this happen. the fact that we're sitting around and haven't even started our COVID trial is troubling - but maybe i'm the only one concerned about this.